Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma
Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma
复制标题
鉴定用于预测肝细胞癌患者生存的潜在预后长非编码 RNA 生物标志物。
DOI：
10.1159/000492507
复制
发表时间：
2018-01-01
影响因子：
--
通讯作者：
Peng, Tao
中科院分区：
文献类型：
--
作者：
Liao, Xiwen;Yang, Chengkun;Peng, Tao
背景/目的：本研究的目的是利用癌症基因组图谱（TCGA）数据集和生物信息学分析，确定预测肝细胞癌（HCC）患者生存的潜在预后长链非编码RNA （lncRNA）生物标志物。方法：采用单因素Cox分析，对TCGA地区HCC患者的RNA测序和临床资料进行预后相关性评估。采用逐步多变量Cox分析建立预后特征，并进行综合分析以评价其预后价值。通过功能评估和生物信息学分析进一步评估预后特征。结果：鉴定出13个差异表达的lncrna (DELs)，并用于构建单个预后特征。高危评分高的患者死亡风险显著增加（校正P < 0.0001，校正风险比= 3.522,95%可信区间= 2.307 ~ 5.376）。在时间依赖的受试者工作特征分析中，该预后特征对HCC生存的预测效果良好，1年、3年和5年生存的曲线下面积分别为0.809、0.782和0.79。对13-DEL预后特征的综合生存分析表明，它是HCC的一个独立因素，比传统临床指标具有更好的预后预测效果。功能评估和生物信息学分析表明，预后特征与细胞周期和过氧化物酶体增殖物激活受体信号通路有关。结论：本研究中发现的新的lncRNA表达特征可能是预测HCC患者预后的潜在生物标志物。(C) 2018作者：s . Karger AG，巴塞尔出版
Background/Aims: The aim of the current study was to identify potential prognostic long non-coding RNA (lncRNA) biomarkers for predicting survival in patients with hepatocellular carcinoma (HCC) using The Cancer Genome Atlas (TCGA) dataset and bioinformatics analysis. Methods: RNA sequencing and clinical data of HCC patients from TCGA were used for prognostic association assessment by univariate Cox analysis. A prognostic signature was built using stepwise multivariable Cox analysis, and a comprehensive analysis was performed to evaluate its prognostic value. The prognostic signature was further evaluated by functional assessment and bioinformatics analysis. Results: Thirteen differentially expressed lncRNAs (DELs) were identified and used to construct a single prognostic signature. Patients with high risk scores showed a significantly increased risk of death (adjusted P < 0.0001, adjusted hazard ratio = 3.522, 95% confidence interval = 2.307-5.376). In the time-dependent receiver operating characteristic analysis, the prognostic signature performed well for HCC survival prediction with an area under curve of 0.809, 0.782 and 0.79 for 1-, 3-and 5-year survival, respectively. Comprehensive survival analysis of the 13-DEL prognostic signature suggested that it serves as an independent factor in HCC, showing a better performance for prognosis prediction than traditional clinical indicators. Functional assessment and bioinformatics analysis suggested that the prognostic signature was associated with the cell cycle and peroxisome proliferator-activated receptor signaling pathway. Conclusions: The novel lncRNA expression signature identified in the present study may be a potential biomarker for predicting the prognosis of HCC patients. (C) 2018 The Author(s) Published by S. Karger AG, Basel